Trials / Completed
CompletedNCT06211153
Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This non-interventional study (NIS) was a retrospective chart review analyzing existing data from patients participating in the asciminib MAP.
Conditions
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2022-12-15
- Completion
- 2022-12-15
- First posted
- 2024-01-18
- Last updated
- 2024-01-18
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT06211153. Inclusion in this directory is not an endorsement.